Antifibrinolytic therapy for aneurysmal subarachnoid haemorrhage
about
Antifibrinolytics (lysine analogues) for the prevention of bleeding in people with haematological disordersHaemostatic drugs for traumatic brain injuryAntifibrinolytic therapy for aneurysmal subarachnoid haemorrhageAntifibrinolytics (lysine analogues) for the prevention of bleeding in patients with haematological disordersAnti-fibrinolytics (lysine analogues) for the prevention of bleeding in patients with haematological disordersHaemostatic drugs for traumatic brain injuryHaemostatic drug therapies for acute spontaneous intracerebral haemorrhageHaemostatic drug therapies for acute primary intracerebral haemorrhageChildren in reviews: methodological issues in child-relevant evidence syntheses.Clinical review: Traumatic brain injury in patients receiving antiplatelet medicationAdvances in the understanding of delayed cerebral ischaemia after aneurysmal subarachnoid haemorrhageIntracisternal administration of tissue plasminogen activator improves cerebrospinal fluid flow and cortical perfusion after subarachnoid hemorrhage in miceGenes influencing coagulation and the risk of aneurysmal subarachnoid hemorrhage, and subsequent complications of secondary cerebral ischemia and rebleedingManagement of aneurysmal subarachnoid hemorrhage.A nested mechanistic sub-study into the effect of tranexamic acid versus placebo on intracranial haemorrhage and cerebral ischaemia in isolated traumatic brain injury: study protocol for a randomised controlled trial (CRASH-3 Trial Intracranial BleePrinciples of neuroanesthesia in aneurysmal subarachnoid hemorrhageTranexamic acid for patients with traumatic brain injury: a randomized, double-blinded, placebo-controlled trial.Effect of tranexamic acid in traumatic brain injury: a nested randomised, placebo controlled trial (CRASH-2 Intracranial Bleeding Study).Brain ischemia in patients with intracranial hemorrhage: pathophysiological reasoning for aggressive diagnostic management.Ultra-early tranexamic acid after subarachnoid hemorrhage (ULTRA): study protocol for a randomized controlled trial.Microthrombosis after experimental subarachnoid hemorrhage: time course and effect of red blood cell-bound thrombin-activated pro-urokinase and clazosentan.The spot sign and tranexamic acid on preventing ICH growth--AUStralasia Trial (STOP-AUST): protocol of a phase II randomized, placebo-controlled, double-blind, multicenter trial.Korean Clinical Practice Guidelines for Aneurysmal Subarachnoid Hemorrhage.Subarachnoid haemorrhage
P2860
Q24186028-BCA7E8CB-8BF9-43CC-AFDF-2CCAFBD718B4Q24188122-BE78B3C7-1640-4A48-8815-424A8937AF7FQ24199107-F48B0886-D76D-48C2-A7FE-FA657E1C6A0AQ24201018-615641CA-C2D8-4B37-BDCF-502713D6197DQ24201514-E387BA4A-F191-4F80-8049-478D840CBD59Q24240304-2EDC8FA3-F2DF-4230-9212-388E118930E2Q24240451-EF8EEA9C-4750-43C3-94C8-2997613CD59EQ24245531-84504B87-ED08-4ADE-9F42-4205BD250748Q24814437-67FDB816-67AA-4F97-908A-982BEC395E21Q26830409-F1A388DE-9013-4AF2-BF72-70BD19207570Q27003355-50BD4686-4762-4054-B245-7DE9EA7815A7Q33577536-C576231F-F246-44A3-A761-AF83A7034A6EQ33626060-962594B2-C52E-445B-ADCC-AD79CD2E94DBQ33645657-9B9D728E-D430-4AF8-968D-2439675895D5Q33909468-51CEB506-0420-4CC5-BF78-EA63F25F8A0AQ34124108-7E54FFBA-067A-44CA-8021-C7956A407D82Q34459644-8A029BA8-DF16-4D85-89FC-6ED88C937F1BQ35083166-C4274848-45DF-4965-925E-7ED175F36075Q38172676-F8DD38B4-B636-4036-9997-F3C264FBFB5AQ40857540-E2655EBA-2071-4A10-8A50-92CE3830FF06Q40980336-4491E400-2745-4C97-B32A-ABCC8CD98328Q50694058-6D572E4D-6F74-4D95-A405-0D35D1D269D1Q53079755-189CA36A-0EDC-4C9E-9689-A0BD796DB979Q57384716-3ABF3C59-7A87-442D-813B-7432165C37C5
P2860
Antifibrinolytic therapy for aneurysmal subarachnoid haemorrhage
description
2003 nî lūn-bûn
@nan
2003 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Antifibrinolytic therapy for aneurysmal subarachnoid haemorrhage
@ast
Antifibrinolytic therapy for aneurysmal subarachnoid haemorrhage
@en
Antifibrinolytic therapy for aneurysmal subarachnoid haemorrhage
@en-gb
Antifibrinolytic therapy for aneurysmal subarachnoid haemorrhage
@nl
type
label
Antifibrinolytic therapy for aneurysmal subarachnoid haemorrhage
@ast
Antifibrinolytic therapy for aneurysmal subarachnoid haemorrhage
@en
Antifibrinolytic therapy for aneurysmal subarachnoid haemorrhage
@en-gb
Antifibrinolytic therapy for aneurysmal subarachnoid haemorrhage
@nl
altLabel
Antifibrinolytic therapy for aneurysmal subarachnoid haemorrhage.
@en
prefLabel
Antifibrinolytic therapy for aneurysmal subarachnoid haemorrhage
@ast
Antifibrinolytic therapy for aneurysmal subarachnoid haemorrhage
@en
Antifibrinolytic therapy for aneurysmal subarachnoid haemorrhage
@en-gb
Antifibrinolytic therapy for aneurysmal subarachnoid haemorrhage
@nl
P2093
P2860
P577
P1476
Antifibrinolytic therapy for aneurysmal subarachnoid haemorrhage
@en
Antifibrinolytic therapy for aneurysmal subarachnoid haemorrhage.
@en
P2093
G J E Rinkel
G J Rinkel
Gabriel JE Rinkel
J van Gijn
Jan van Gijn
M Vermeulen
Marinus Vermeulen
P2860
P304
P356
10.1002/14651858.CD001245
P407
P577
2000-01-01T00:00:00Z
2003-01-01T00:00:00Z
2003-04-22T00:00:00Z